73 related articles for article (PubMed ID: 25738885)
1. Use of the disulfiram/copper complex for breast cancer chemoprevention in MMTV-erbB2 transgenic mice.
Yang Y; Deng Q; Feng X; Sun J
Mol Med Rep; 2015 Jul; 12(1):746-52. PubMed ID: 25738885
[TBL] [Abstract][Full Text] [Related]
2. Curcumin induces apoptosis in breast cancer cell lines and delays the growth of mammary tumors in neu transgenic mice.
Masuelli L; Benvenuto M; Fantini M; Marzocchella L; Sacchetti P; Di Stefano E; Tresoldi I; Izzi V; Bernardini R; Palumbo C; Mattei M; Lista F; Galvano F; Modesti A; Bei R
J Biol Regul Homeost Agents; 2013; 27(1):105-19. PubMed ID: 23489691
[TBL] [Abstract][Full Text] [Related]
3. Buformin inhibits the stemness of erbB-2-overexpressing breast cancer cells and premalignant mammary tissues of MMTV-erbB-2 transgenic mice.
Parris AB; Zhao Q; Howard EW; Zhao M; Ma Z; Yang X
J Exp Clin Cancer Res; 2017 Feb; 36(1):28. PubMed ID: 28193239
[TBL] [Abstract][Full Text] [Related]
4. Effect of annatto-tocotrienols supplementation on the development of mammary tumors in HER-2/neu transgenic mice.
Pierpaoli E; Viola V; Barucca A; Orlando F; Galli F; Provinciali M
Carcinogenesis; 2013 Jun; 34(6):1352-60. PubMed ID: 23430951
[TBL] [Abstract][Full Text] [Related]
5. FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice.
Zhao Q; Parris AB; Howard EW; Zhao M; Ma Z; Guo Z; Xing Y; Yang X
Sci Rep; 2017 Sep; 7(1):11306. PubMed ID: 28900173
[TBL] [Abstract][Full Text] [Related]
6. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression.
Zhang Q; Sakamoto K; Liu C; Triplett AA; Lin WC; Rui H; Wagner KU
Cancer Res; 2011 Dec; 71(24):7513-24. PubMed ID: 22037875
[TBL] [Abstract][Full Text] [Related]
8. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells.
Cao Y; Luo JL; Karin M
Proc Natl Acad Sci U S A; 2007 Oct; 104(40):15852-7. PubMed ID: 17890319
[TBL] [Abstract][Full Text] [Related]
9. Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway.
El-Ashmawy NE; Khedr NF; El-Bahrawy HA; Abo Mansour HE
Tumour Biol; 2017 May; 39(5):1010428317692235. PubMed ID: 28459206
[TBL] [Abstract][Full Text] [Related]
10. Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.
Farabaugh SM; Chan BT; Cui X; Dearth RK; Lee AV
Cell Commun Signal; 2016 Oct; 14(1):25. PubMed ID: 27765041
[TBL] [Abstract][Full Text] [Related]
11. Co-opted integrin signaling in ErbB2-induced mammary tumor progression.
Carraway KL; Sweeney C
Cancer Cell; 2006 Aug; 10(2):93-5. PubMed ID: 16904607
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma.
Pierpaoli E; Damiani E; Orlando F; Lucarini G; Bartozzi B; Lombardi P; Salvatore C; Geroni C; Donati A; Provinciali M
Carcinogenesis; 2015 Oct; 36(10):1169-79. PubMed ID: 26168818
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
[TBL] [Abstract][Full Text] [Related]
14. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram/copper targets stem cell-like ALDH
Jin N; Zhu X; Cheng F; Zhang L
J Cell Biochem; 2018 Aug; 119(8):6882-6893. PubMed ID: 29665144
[TBL] [Abstract][Full Text] [Related]
16. β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression.
Schade B; Lesurf R; Sanguin-Gendreau V; Bui T; Deblois G; O'Toole SA; Millar EK; Zardawi SJ; Lopez-Knowles E; Sutherland RL; Giguère V; Kahn M; Hallett M; Muller WJ
Cancer Res; 2013 Jul; 73(14):4474-87. PubMed ID: 23720052
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Wnt signaling activity for growth suppression induced by quercetin in 4T1 murine mammary cancer cells.
Kim H; Seo EM; Sharma AR; Ganbold B; Park J; Sharma G; Kang YH; Song DK; Lee SS; Nam JS
Int J Oncol; 2013 Oct; 43(4):1319-25. PubMed ID: 23900432
[TBL] [Abstract][Full Text] [Related]
18. Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo.
Chen J; Zeng J; Xin M; Huang W; Chen X
Horm Metab Res; 2011 Sep; 43(10):681-6. PubMed ID: 21932171
[TBL] [Abstract][Full Text] [Related]
19. Tocotrienols inhibit AKT and ERK activation and suppress pancreatic cancer cell proliferation by suppressing the ErbB2 pathway.
Shin-Kang S; Ramsauer VP; Lightner J; Chakraborty K; Stone W; Campbell S; Reddy SA; Krishnan K
Free Radic Biol Med; 2011 Sep; 51(6):1164-74. PubMed ID: 21723941
[TBL] [Abstract][Full Text] [Related]
20. Disulfiram modulated ROS-MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties.
Yip NC; Fombon IS; Liu P; Brown S; Kannappan V; Armesilla AL; Xu B; Cassidy J; Darling JL; Wang W
Br J Cancer; 2011 May; 104(10):1564-74. PubMed ID: 21487404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
